Why Mito AI Verisight Use Cases Team Contact Blog Insights Login
Oncology-First Clinical Intelligence

Keeping you
Ahead of Ready.

Mito AI is an oncology-first clinical intelligence platform that helps biopharma teams turn fast-moving scientific and clinical data into actionable insights — embedded in decision-ready workflows, with the transparency and control that complex oncology decisions demand.

Request a Pilot Explore Verisight
The Problem

Pharma teams are drowning in scientific flux

The bottleneck is no longer access to data. It is turning fragmented, noisy evidence into trusted, decision-ready insights at speed.

01
Evidence Explosion
Publications, congresses, guidelines, labels and field insights move faster than any team can synthesise manually — and suffer from an absence of unified ontology and shared lexicon.
02
Decision Pressure
Strategy and field teams need defensible answers for HCPs, investors and regulators in days or hours — not the weeks that manual synthesis requires.
03
Trust Gap
Generic AI is fast, but life sciences decisions require auditability, disease context, evidence hierarchy and expert control — none of which general-purpose LLMs provide.

Mito AI platform performance dashboard — five dimensions of clinical intelligence

Time to insight
< 1 hr
From data drop to "so what"
Congress readout live. Synthesis with clinical context, competitive framing and asset implications — ready in under an hour.
Synthesis at scale
100's
Multi-modal sources. One query.
Trials, labels, guidelines, congress, field signals — simultaneously. No cognitive ceiling. No coverage gaps.
Raising the floor · Breaking the ceiling
Expert-grade. Every query. Every function.
Output quality is no longer a function of who you ask. Best practice codified, standardised and available across every team — from the most experienced Medical Director to the MSL in month one.
floor raised ceiling broken
Signal to noise
10,000+
Entities resolved. Noise filtered.
Precision at entity level is the enemy of hallucination. The model operates on a clean, ranked, auditable signal.
Compounding intelligence
2x
A learning system. Not a lookup.
Every query enriches a shared evidence layer that doesn't reset. Each new signal raises the intelligence of everything before it.
"
In oncology, the evidence base that determines every critical decision — how to design the trial, whether to do the deal, how to sequence the indication — is growing faster than any team can synthesise manually.
Clinical Decision Intelligence — Mito AI
The Platform

VERISIGHT by Mito AI

The governed clinical intelligence layer that closes the synthesis gap — for every function, at every stage of the asset lifecycle. Trusted inputs. Auditable outputs. Designed for scientific interrogation.

Request Demo
🗂
Specialist Workflows
Predefined workflows built around the priorities that matter most across Medical Affairs, Clinical Development, BD & Early Commercial and Insights & Analytics — covering high-value topics like SoC mapping, evidence synthesis, competitive review, evidence gaps and indication prioritisation.
💬
Q-Bar
For exploratory scientific interrogation on any topic of interest. Ask open-ended questions across the full evidence base, surface signals you didn't know to look for, and go deeper on what matters. Translate insights into executive presentations in real-time, ready to share.
📚
Evidence Library
All external evidence — publications, abstracts, labels, guidelines, trials, congress — and your own internal data connected on a unified oncology data architecture with shared lexicon and entity resolution across every source.
🔒
Governance Built-In
Every output structured, cited, editable and shareable. Role-based access, versioning and full audit trail — built in from day one, not bolted on.
Before Verisight
✕Evidence moves faster than any team can synthesise manually
✕Every landscape, diligence pack and field brief built from scratch — every time
✕R&D, BD and Medical Affairs working from different versions of the same evidence
✕Generic AI outputs no regulated function can sign off on
✕No audit trail — and no way to show where the claim comes from
With Verisight
✓First-pass evidence synthesis in hours — sourced, structured, expert-ready
✓A single evidence layer connected across the clinical entities that matter — genes, biomarkers, MoA, modalities, trial attributes and treatment settings
✓Decision-grade outputs — fast, defensible, traceable and reusable
✓Built for regulated environments from day one — every output source-cited and versioned
✓Decision workflows designed to keep you in control throughout — with the ability to take over at any step, not just at output review
Use Cases

One platform. Every function.

The same governed evidence layer — curated external evidence combined with your own data, source-cited, versioned and audit-ready — serves every team across the asset lifecycle.

Medical Affairs
The clinical intelligence layer for scientific strategy, field readiness and stakeholder engagement
Verisight connects external evidence with your own field signals, AdBoard outputs and CRM data — so Medical Affairs teams are always ahead of the science, not catching up to it.
  • Evidence Gap Generation & Prioritization
  • HCP Sentiment Analysis
  • Pressure Test Key Messages
  • Objection Mining and Handling
  • SoC Momentum and Drift

We work with you to configure these workflows to your organisation's context, data environment and business rules — while preserving best practice from years of advisory experience in Medical Affairs.

Explore what this looks like for your team →
Clinical Development
Defensible trial design intelligence, continuously updated
Verisight gives R&D teams a live view of the evolving SoC, competitor trial landscape and regulatory precedent — so every design decision is grounded in current evidence, not the last cycle.
  • Clinical Intelligence on potential targets, MoAs and modalities
  • Target validation and value modelling
  • Clinical Trial Design Standards and Review
  • Comparative Efficacy and Safety Benchmarking

We work with you to configure these workflows to your programme context, tumour area and development stage.

Explore what this looks like for your team →
BD & Early Commercial
Asset evaluation, indication prioritisation and path-to-market evaluation — on demand
Where does this asset win, and does the thesis still hold against the live landscape? Verisight answers that on demand — combining external evidence with your own strategy docs, CI and market research.
  • Asset TPP vs Evolving SoC
  • Define the Winning Therapeutic Index
  • Indication Prioritisation and White Space Analysis
  • SoC Scenario Planning — base case, disruption, competitive setback
  • Treatment Sequencing and Displacement Mapping

We work with you to configure these workflows to your asset, portfolio context and deal or launch timeline.

Explore what this looks like for your team →
Insights & Analytics
Scalable, reusable intelligence — across every function, every cycle
Verisight replaces bespoke one-off requests with a governed intelligence layer that compounds across functions and congress cycles — and serves leadership with board-ready intelligence at the pace of the field.
  • Competitive Pipeline Tracking and Threat Assessment
  • Congress Intelligence — available across all functions simultaneously
  • Executive Briefings synthesised in hours from large, multi-source datasets
  • Dynamic benchmarking of assets, treatment algorithms and SoC impact
  • Asset Value Modelling — on demand

We work with you to define the intelligence cadence, output formats and distribution model that fits how your organisation works.

Explore what this looks like for your team →
The Mito Advantage

Why generic AI cannot solve this

Four structural problems in oncology intelligence that general-purpose LLMs cannot address — and how Mito AI solves each one.

01
The Lexicon Challenge
Mito Answer
Different names, acronyms and contexts for the same clinical concept. Mito AI resolves this through entity normalisation and disambiguation across the full oncology evidence base — unified in our knowledge mesh.
02
The Relevance Problem
Mito Answer
Evidence only matters in a specific setting, line, population and biomarker context. We decompose science into atomic units and layer proprietary data constructs that encode relevance into every answer.
03
The Hierarchy Problem
Mito Answer
A pivotal Phase 3 trial and a congress poster should not carry equal weight. Mito AI grounds synthesis in ranked evidence, source audit and expert review — so outputs reflect the actual evidence hierarchy.
04
The Governance Problem
Mito Answer
High-stakes outputs need transparency, control, versioning and reusability. Verisight delivers editable, auditable, shareable workflows that compound institutional knowledge across every function.
Precision Built Over Years

Oncology precision not replicable overnight

The clinical inference architecture behind Verisight rests on a proprietary knowledge mesh built specifically for oncology — connecting entities, settings and evidence that general-purpose AI cannot resolve.

Mito AI Knowledge Mesh Network diagram of Mito AI's oncology knowledge mesh connecting atomic entities through clinical inference to relevance algorithms. Atomic Entities Clinical Inference Relevance Layer Genes & biomarkers (1,500+ & growing) Tumour histology (500+) Tumour group (n=17) Mechanism of action Modality Line of therapy Treatment setting Asset & drug Trial design Endpoints Development stage Evidence ranking Population match Competitive context Unmet need signal Geography Hover any node to explore connections
Atomic entities Clinical inference Relevance algorithms
Our Philosophy

AI that augments expertise.
Not replaces it.

We build at the intersection of generative and agentic AI — and we are deliberate about where each belongs. Generative AI accelerates synthesis. Agentic AI handles orchestration. Human expertise — the oncologist, the MSL, the strategist — remains in charge of what matters: judgment, context and the decision itself.

We don't believe AI should replace scientific expertise in pharma R&D. The complexity of oncology, the stakes of the decisions, and the regulatory environment all demand a human who understands the science and owns the process as much as the outcome. Our role is to make that human faster, better-informed and more defensible — not to remove them from the loop. With Verisight, the user is in control throughout.

That means striking the right balance between control and delegation at every layer of the platform. We'd love to share how we think about that.

Curious how we do it? Let's talk →
Generative AI
Accelerates synthesis
Turns fragmented, multi-source evidence into structured, cited, expert-ready outputs in hours — not days.
Agentic AI
Handles orchestration
Manages multi-step workflows, data retrieval and synthesis pipelines — while keeping the human in control at every decision point.
Human Expertise
Owns the outcome
Judgment, context and the decision itself. Always. Verisight is designed to augment the expert — not replace them.
Getting Started

How we work together

We work with a small number of biopharma partners at a time — with depth and serviced engagement to make Verisight work for your specific workflows.

01
Mutual Discovery
Immersion session with target expert users to map your priority use cases, workflows and decision pain points.
02
Pilot & Feedback
6–8 week hands-on pilot with defined success criteria, collaborative workshops and iterative user feedback.
03
Platform Tune-Up
Refine and configure Verisight based on pilot learnings — use case prioritisation, output formats, evidence coverage.
04
Roll Out
Expand to wider teams and additional tumour areas with confidence — encoded into a proven playbook.
Next Step

The next step is a conversation.

Early partners shape the product, influence use case prioritisation and benefit from full serviced onboarding. First meaningful output in week 1. Fully configured platform by week 8.

Request a Pilot Live: Verisight
The Team

Medical and technology expertise combined

Mito AI combines biopharma domain expertise, product design, data engineering and a pragmatic understanding of how pharma teams make decisions.

DT
Dr. Debasish Talukdar
Founder & CEO
Physician · ex-Bain · Former Pharma Services CEO. Operating at the intersection of science, data and strategy for over two decades, with a specialist focus on oncology asset development and commercialisation.
LinkedIn
MP
Marzi Jehangir Patell
Co-Founder & CTO
Engineer · Former Digital Transformation Partner, Bain & Co. Leads product design, platform architecture and delivery — with deep expertise in how clinical intelligence workflows must operate for expert users in practice.
LinkedIn
Get in Touch

Let's talk about your use case

Contact us to ask questions, request a pilot or explore how Verisight fits your workflows.

📬
🏢
Registered Office
Mitochon Ltd · 9th Floor, 107 Cheapside
London, UK, EC2V 6DN
🔗
Follow Us
LinkedIn X / Twitter